Exploring the promising yet challenging results of dual targeting BTK and CD52 in treating poor-prognosis chronic lymphocytic leukemia
Exploring how antisense oligodeoxynucleotides are reprogramming cancer cells by targeting PKA subunits, with detailed experimental data and clinical implications.